PepTalk24 Jan 2020
Celebrating its nineteenth year, PepTalk covers a wide spectrum of applied protein sciences with emphasis on upstream R&D engineering to downstream biologics production and provides a casual forum for intensive learning and networking with key players of the industry.
Are you attending? Be sure not to miss Eleonora Cerasoli (Albumedix Science Manager) presenting the following:
Recombinant albumin role in biologics formulation. Glucagon case study.
Degradation of biopharmaceuticals is a major source of dosage form and storage instability and may lead to a series of problems during manufacturing, handling and post administration. Formulations must therefore be developed to minimise the occurrence of chemical and physical degradation, in particular when these species affect the critical quality attributes impairing the safety/efficacy of the drug product. It is well-known that recombinant human serum albumin has the ability to stabilise proteins in solution preventing adsorption, aggregation and oxidation. The stabilising ability stems from some of the roles albumin performs in blood, such as a carrier of small hydrophobic entities, participation in the control of pH and osmotic pressure and affording the majority of the antioxidant capabilities present in blood. Recombinant Human Albumin (rAlb) is therefore a promising stabilizer for hard-to-formulate biopharmaceuticals. In this study we are showing the advantages of using Albumedix® Recombumin®, a recombinant albumin product, as a stabilizing agent for a model biopharmaceutical of complex behaviour, Glucagon.
Interested in viewing the full agenda for PepTalk? Click here!